Phase I study of the safety, tolerability, and potential therapeutic dose of OMT-110 for patients with refractory metastatic Colorectal Cancer. Jeon Y, Jung M, Jeong B, Lee H, et al. BMC Cancer 2025;25:937.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jeon Y, Jung M, Jeong B, Lee H, et al. Phase I study of the safety, tolerability, and potential therapeutic dose of OMT-110 for patients with refractory metastatic Colorectal Cancer. BMC Cancer 2025;25:937.
PMID: 40414889